Population pharmacokinetics of unbound mycophenolic acid in pediatric and young adult patients undergoing allogeneic hematopoietic cell transplantation

Journal of Clinical Pharmacology

Volumn 52, Issue 11, 2012, Pages 1665-1675

  Kim, Hyewon ^a   Long Boyle, Janel ^b   Rydholm, Nancy ^a   Orchard, Paul J ^a   Tolar, Jakub ^a   Smith, Angela R ^a   Jacobson, Pamala ^a   Brundage, Richard ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

acute graft vs host disease; hematopoietic cell transplantation; Mycophenolate; mycophenolic acid; pediatric; pharmacokinetics

Indexed keywords

BILIRUBIN; CYCLOSPORIN; CYCLOSPORIN A; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; SERUM ALBUMIN;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; COMPARTMENT MODEL; CREATININE CLEARANCE; DRUG ABSORPTION; DRUG DOSE REDUCTION; DRUG ELIMINATION; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; LIVER DYSFUNCTION; POPULATION MODEL; POPULATION RESEARCH;

ADOLESCENT; ADULT; AREA UNDER CURVE; CHILD; CHILD, PRESCHOOL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; MALE; MODELS, BIOLOGICAL; MYCOPHENOLIC ACID; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84867533092     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011422814     Document Type: Article

References (39)

1. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998 ; 34: 429-455 (Pubitemid 28273453)
2. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet. 2007 ; 46: 13-58 (Pubitemid 46091591)
3. Jacobson P, Rogosheske J, Barker JN, et al. Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. Clin Pharmacol Ther. 2005 ; 78: 486-500 (Pubitemid 41698903)
4. Nash RA, Johnston L, Parker P, et al. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2005 ; 11: 495-505 (Pubitemid 40862446)
5. Giaccone L, McCune JS, Maris MB, et al. Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. Blood. 2005 ; 106: 4381-4388 (Pubitemid 41775952)
6. Maris MB, Niederwieser D, Sandmaier BM, et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood. 2003 ; 102: 2021-2030 (Pubitemid 37122375)
7. Parikh CR, McSweeney PA, Korular D, et al. Renal dysfunction in allogeneic hematopoietic cell transplantation. Kidney Int. 2002 ; 62: 566-573 (Pubitemid 34779769)
8. Kaplan B, Meier-Kriesche HU, Friedman G, et al. The effect of renal insufficiency on mycophenolic acid protein binding. J Clin Pharmacol. 1999 ; 39: 715-720
9. Weber LT, Shipkova M, Lamersdorf T, et al. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. J Am Soc Nephrol. 1998 ; 9: 1511-1520 (Pubitemid 28354563)
10. Shaw LM, Mick R, Nowak I, et al. Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function. J Clin Pharmacol. 1998 ; 38: 268-275 (Pubitemid 28144932)
11. van Hest RM, van Gelder T, Vulto AG, et al. Pharmacokinetic modelling of the plasma protein binding of mycophenolic acid in renal transplant recipients. Clin Pharmacokinet. 2009 ; 48: 463-476
12. de Winter BC, van Gelder T, Sombogaard F, et al. Pharmacokinetic role of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients. J Pharmacokinet Pharmacodyn. 2009 ; 36: 541-564
13. Reiss U, Cowan M, McMillan A, et al. Hepatic venoocclusive disease in blood and bone marrow transplantation in children and young adults: incidence, risk factors, and outcome in a cohort of 241 patients. J Pediatr Hematol Oncol. 2002 ; 24: 746-750 (Pubitemid 35448741)
14. Weber LT, Shipkova M, Armstrong VW, et al. The harmacokinetic- pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy. J Am Soc Nephrol. 2002 ; 13: 759-768 (Pubitemid 34183943)
15. Jacobson PA, Rydhom N, Huang J, et al. High-unbound mycophenolic acid concentrations in an infant on peritoneal dialysis following hematopoietic cell transplant. Bone Marrow Transplant. 2007 ; 40: 911-912 (Pubitemid 350020329)
16. Kaplan B, Gruber SA, Nallamathou R, et al. Decreased protein binding of mycophenolic acid associated with leukopenia in a pancreas transplant recipient with renal failure. Transplantation. 1998 ; 65: 1127-1129 (Pubitemid 28208433)
17. Mudge DW, Atcheson BA, Taylor PJ, et al. Severe toxicity associated with a markedly elevated mycophenolic acid free fraction in a renal transplant recipient. Ther Drug Monit. 2004 ; 26: 453-455 (Pubitemid 38989666)
18. Annesley TM, Clayton LT. Quantification of mycophenolic acid and glucuronide metabolite in human serum by HPLC-tandem mass spectrometry. Clin Chem. 2005 ; 51: 872-877 (Pubitemid 40577924)
19. Rockville, MD: Center for Drug Evaluation and Research ; 1998 :
20. Kuypers DR, Vanrenterghem Y, Squifflet JP, et al. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther Drug Monit. 2003 ; 25: 609-622 (Pubitemid 37238896)
21. Gonzalez-Roncero FM, Govantes MA, Chaves VC, et al. Influence of renal insufficiency on pharmacokinetics of ACYL-glucuronide metabolite of mycophenolic acid in renal transplant patients. Transplant Proc. 2007 ; 39: 2176-2178 (Pubitemid 47432695)
22. Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther. 200271: 115-121 (Pubitemid 34271114)
23. Sun H, Frassetto L, Benet LZ. Effects of renal failure on drug transport and metabolism. Pharmacol Ther. 2006109: 1-11
24. Picard N, Ratanasavanh D, Premaud A, et al. Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos. 2005 ; 33: 139-146 (Pubitemid 40023525)
25. Vilay AM, Churchwell MD, Mueller BA. Clinical review: drug metabolism and nonrenal clearance in acute kidney injury. Crit Care. 200812: 235
26. Herget-Rosenthal S, Glorieux G, Jankowski J, et al. Uremic toxins in acute kidney injury. Semin Dial. 2009 ; 22: 445-448
27. Patterson SE, Cohn VH. Hepatic drug metabolism in rats with experimental chronic renal failure. Biochem Pharmacol. 1984 ; 33: 711-716 (Pubitemid 14166437)
28. Taburet AM, Singlas E. Drug interactions with antiviral drugs. Clin Pharmacokinet. 1996 ; 30: 385-401 (Pubitemid 26178257)
29. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008 ; 64: 1147-1161
30. Morgan DJ, McLean AJ. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease: an update. Clin Pharmacokinet. 1995 ; 29: 370-391
31. Reichen J. The role of the sinusoidal endothelium in liver function. News Physiol Sci. 199914: 117-121
32. Furlan V, Demirdjian S, Bourdon O, et al. Glucuronidation of drugs by hepatic microsomes derived from healthy and cirrhotic human livers. J Pharmacol Exp Ther. 1999 ; 289: 1169-1175 (Pubitemid 29191280)
33. Cheuk DK, Wang P, Lee TL, et al. Risk factors and mortality predictors of hepatic veno-occlusive disease after pediatric hematopoietic stem cell transplantation. Bone Marrow Transplant. 2007 ; 40: 935-944 (Pubitemid 350048191)
34. Chen N, Aleksa K, Woodland C, et al. ntogeny of drug elimination by the human kidney. Pediatr Nephrol. 2006 ; 21: 160-168 (Pubitemid 43115865)
35. Strassburg CP, Strassburg A, Kneip S, et al. Developmental aspects of human hepatic drug glucuronidation in young children and adults. Gut. 2002 ; 50: 259-265 (Pubitemid 34087942)
36. Court MH. Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system. Drug Metab Rev. 2010 ; 42: 209-224
37. Naderer OJ, Dupuis RE, Heinzen EL, et al. The influence of norfloxacin and metronidazole on the disposition of mycophenolate mofetil. J Clin Pharmacol. 2005 ; 45: 219-226 (Pubitemid 40490446)
38. Barraclough KA, Lee KJ, Staatz CE. Pharmacogenetic influences on mycophenolate therapy. Pharmacogenomics. 2010 ; 11: 369-390
39. Jacobson P, Long J, Rogosheske J, et al. High unbound mycophenolic acid concentrations in a hematopoietic cell transplantation patient with sepsis and renal and hepatic dysfunction. Biol Blood Marrow Transplant. 2005 ; 11: 977-978 (Pubitemid 41754715)